Let's break down Indoco Remedies Limited (INDOCO) — from its financial performance to how the market is valuing the stock.
Indoco Remedies Revenue Trend
Revenue fell 8.9% year-over-year to ₹1,665 Cr in FY2025 for Indoco Remedies Limited.
On a 10-year view, revenue grew at 6.9% per year from ₹857 Cr to ₹1,665 Cr. Respectable, though not in the high-growth bracket.
In terms of scale, Indoco Remedies Limited's ₹1,665 Cr in annual revenue positions it as a mid-sized pharmaceuticals company.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,665 Cr | -8.9% |
| FY2024 | ₹1,827 Cr | +9.3% |
| FY2023 | ₹1,671 Cr | +8.3% |
| FY2022 | ₹1,543 Cr | +24.3% |
| FY2021 | ₹1,242 Cr | — |
View Indoco Remedies Limited's full 10-year revenue trend with CAGR analysis →
Indoco Remedies Profitability
After earning ₹97.0 Cr in FY2024, Indoco Remedies Limited swung to a loss of ₹78.0 Cr in FY2025.
FY2025 diluted EPS of ₹-8.45 was down from the ₹10.51 reported in FY2024.
Is Indoco Remedies Undervalued
Running the numbers through the P/E Ratio model gives a fair value of ₹256 for Indoco Remedies Limited.
Indoco Remedies Limited shares are currently trading at ₹207.43.
Craytheon also calculates intrinsic value using the EPS Growth model. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹256 | 23.4% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
See all valuation models for Indoco Remedies Limited with detailed assumptions →
Indoco Remedies Shareholding Pattern
At 58.9%, the promoter stake has been flat for the past 4 quarters.
FII ownership stands at 0.9%, down from the 1.2% recorded a year ago.
DII holding is at 18.1%, down from 19.0% in the year-ago quarter.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 58.9% | 0.9% | 18.1% | 21.9% |
| Dec 2025 | 58.9% | 1.1% | 18.1% | 21.8% |
| Sep 2025 | 58.9% | 1.2% | 18.2% | 21.6% |
| Jun 2025 | 58.9% | 1.2% | 19.0% | 20.8% |
Track quarterly shareholding changes for Indoco Remedies Limited →
Indoco Remedies Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹24.30B, up 13.3% YoY from ₹21.45B.
Property, Plant & Equipment accounts for 45.7% of the total, ahead of Inventories (17.3%) and Receivables (14.5%).
Capital structure: 41.9% equity, 40.9% debt, 17.2% operating liabilities. Over the year, debt is up 47.9% and equity is down 8.3%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 120.96M |
| Receivables | 3.52B |
| Inventories | 4.19B |
| Property, Plant & Equipment | 11.10B |
| Investments | 14.63M |
| Intangibles & Goodwill | 1.92B |
| Other Assets | 3.42B |
| Category | Value |
|---|---|
| Equity | 10.18B |
| Short-term Debt | 4.51B |
| Long-term Debt | 5.43B |
| Trade Payables | 2.08B |
| Other Liabilities | 2.10B |
What Stands Out About Indoco Remedies
To sum up Indoco Remedies Limited's financial position: the data paints a clear picture for investors evaluating this pharmaceuticals stock.
Revenue of ₹1,665 Cr in FY2025, down 8.9% year-over-year.
Long-term revenue has been compounding at 6.9% annually over 10 years.
The company reported a net loss of ₹78.0 Cr in FY2025.
The P/E Ratio model implies 23.4% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Indoco Remedies Limited's detailed profile on Craytheon.